Proof of Concept Study to Evaluate the Efficacy and Safety of BMS-931699 (Lulizumab) or BMS-986142 in Primary Sjögren's Syndrome

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2016
The primary objective of this study is to evaluate the efficacy of treatment with either lulizumab or BMS-986142 versus placebo in subjects with moderate to severe primary Sjögren\'s syndrome as measured by the change from baseline in ESSDAI at Week 12 between active treatment arms (lulizumab or BMS-986142, respectively) and the placebo arm.
Epistemonikos ID: 06d90ba108fb0904ac9e0e5a57198c8a7d71836d
First added on: May 17, 2024